We are live on ! Find out more
LYEL icon

Lyell Immunopharma
LYEL

77 hedge funds and large institutions have $662M invested in Lyell Immunopharma in 2021 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 27 increasing their positions, 11 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

145% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 11

136% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 11

24% more funds holding

Funds holding: 62 → 77 (+15)

0.05% more ownership

Funds ownership: 1.72% → 1.78% (+0.05%)

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

46% less capital invested

Capital invested by funds: $1.22B → $662M (-$559M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $148K

Holders
77
Holders Change
+15
Holders Change %
+24.19%
% of All Funds
1.18%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
26
Increased
27
Reduced
11
Closed
11
Calls
–
Puts
$148K
Net Calls
-$148K
Net Calls Change
-$148K

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$16.5M
2
E
Ergoteles
New York
+$11.2M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.62M
4
BlackRock
BlackRock
New York
+$6.38M
5
AP
Adero Partners
California
+$5.48M

Top Sellers

1
HA
HHLR Advisors
Cayman Islands
-$34.8M
2
DIG
Dragoneer Investment Group
California
-$14.8M
3
Federated Hermes
Federated Hermes
Pennsylvania
-$3.5M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$1.9M
5
MM
MWG Management
British Virgin Islands
-$1.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
CGL
51
Clarius Group LLC
Washington
$127K +$183K +820 New
ECM
52
ExodusPoint Capital Management
New York
$120K +$173K +775 New
EGM
53
Engineers Gate Manager
New York
$114K +$164K +735 New
PPA
54
Parametric Portfolio Associates
Washington
$114K +$165K +739 New
UBS Group
55
UBS Group
Switzerland
$112K +$158K +707 +5,438%
Deutsche Bank
56
Deutsche Bank
Germany
$111K +$8.25K +37 +5%
New York State Common Retirement Fund
57
New York State Common Retirement Fund
New York
$108K +$44.6K +200 +40%
California State Teachers Retirement System (CalSTRS)
58
California State Teachers Retirement System (CalSTRS)
California
$99K – – –
AIG
59
American International Group
New York
$97K -$4.24K -19 -3%
Walleye Capital
60
Walleye Capital
New York
$93K +$134K +600 New
AGM
61
Alpine Global Management
New York
$91K +$131K +588 New
Invesco
62
Invesco
Georgia
$89K +$129K +577 New
Qube Research & Technologies (QRT)
63
Qube Research & Technologies (QRT)
United Kingdom
$87K +$126K +563 New
CIBC Asset Management
64
CIBC Asset Management
Ontario, Canada
$81K +$117K +526 New
Susquehanna International Group
65
Susquehanna International Group
Pennsylvania
$80K -$242K -1,086 -68%
TRCT
66
Tower Research Capital (TRC)
New York
$68K +$70.9K +318 +256%
SO
67
STRS Ohio
Ohio
$41K – – –
Royal Bank of Canada
68
Royal Bank of Canada
Ontario, Canada
$40K +$26.3K +118 +84%
Legal & General Group
69
Legal & General Group
United Kingdom
$17K – – –
AIP
70
Ameritas Investment Partners
Nebraska
$14K – – –
Simplex Trading
71
Simplex Trading
Illinois
$12K +$18.3K +82 New
CAPTRUST Financial Advisors
72
CAPTRUST Financial Advisors
North Carolina
$6K +$8.25K +37 +1,850%
Daiwa Securities Group
73
Daiwa Securities Group
Japan
$5K +$7.81K +35 New
HNWAG
74
High Net Worth Advisory Group
Florida
$4K +$5.58K +25 New
PCG
75
Private Capital Group
Connecticut
$2K +$2.23K +10 New
1 2
3
4

LYEL Hedge Fund Activity: Q4 2021 in Review

77 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q4 2021, worth a combined $662M — down 46% from $1.22B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new LYEL positions and 11 closed out — a net gain of 15 holders — while 27 added to existing stakes and 11 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $16.5M. The largest seller was HHLR Advisors, exiting entirely with an estimated $34.8M sold.

  • 77 institutional investors held Lyell Immunopharma (LYEL) as of Q4 2021, up from 62 in Q3 2021.
  • Funds reported $662M of Lyell Immunopharma stock for Q4 2021, down 46% quarter-over-quarter.
  • 26 funds opened new Lyell Immunopharma positions in Q4 2021 and 11 closed out, a net change of +15 holders.
  • The largest Lyell Immunopharma buyer in Q4 2021 was T. Rowe Price Associates, an estimated $16.5M added.
  • The largest Lyell Immunopharma seller in Q4 2021 was HHLR Advisors, an estimated $34.8M sold.

Based on aggregated 13F filings for Q4 2021.